Literature DB >> 24520002

Concise review: cancer cells escape from oncogene addiction: understanding the mechanisms behind treatment failure for more effective targeting.

Francesca Pellicano1, Leena Mukherjee, Tessa L Holyoake.   

Abstract

Oncogene addiction describes the dependence of some cancers on one or a few genes for their survival. Inhibition of the corresponding oncoproteins can lead to dramatic responses. However, in some cases, such as chronic myeloid leukemia (CML), a disease characterized by the presence of the abnormal fusion tyrosine kinase BCR-ABL, cancer stem cells may never acquire addiction to the oncogene that drives disease development. The suggested mechanism(s) for treatment failure include a quiescent stem cell population capable of reinstating disease, high levels of oncoprotein expression, or acquired mutations in the oncogene. In this review, we discuss the evidence for oncogene addiction in several solid tumors and their potential escape mechanism(s) with a particular focus on CML stem cells.
© 2014 AlphaMed Press.

Entities:  

Keywords:  Adult stem cells; BCR-ABL; Cancer cells; Chronic myeloid leukemia; Hemopoietic stem cells; Oncogene addiction; Tyrosine kinase inhibitors

Mesh:

Year:  2014        PMID: 24520002     DOI: 10.1002/stem.1678

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  16 in total

1.  Authors' Reply to Crampe and Langabeer: Technical Issues Behind Molecular Monitoring in Chronic Myeloid Leukemia.

Authors:  Elia Mattarucchi; Francesco Pallotti; Rosario Casalone
Journal:  Mol Diagn Ther       Date:  2015-08       Impact factor: 4.074

2.  Technical Issues Behind Molecular Monitoring in Chronic Myeloid Leukemia.

Authors:  Elia Mattarucchi; Francesco Pallotti; Rosario Casalone
Journal:  Mol Diagn Ther       Date:  2015-06       Impact factor: 4.074

3.  Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera.

Authors:  T Tsuruta-Kishino; J Koya; K Kataoka; K Narukawa; Y Sumitomo; H Kobayashi; T Sato; M Kurokawa
Journal:  Oncogene       Date:  2017-01-09       Impact factor: 9.867

4.  Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.

Authors:  Eric D Wirtz; Daisuke Hoshino; Anthony T Maldonado; Darren R Tyson; Alissa M Weaver
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2015-06       Impact factor: 6.223

5.  A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.

Authors:  Leyuan Ma; Yi Shan; Robert Bai; Liting Xue; Christopher A Eide; Jianhong Ou; Lihua J Zhu; Lloyd Hutchinson; Jan Cerny; Hanna Jean Khoury; Zhi Sheng; Brian J Druker; Shaoguang Li; Michael R Green
Journal:  Sci Transl Med       Date:  2014-09-03       Impact factor: 17.956

6.  Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release.

Authors:  Yuki Ishii; May Keu Nhiayi; Edison Tse; Jonathan Cheng; Michele Massimino; Donald L Durden; Paolo Vigneri; Jean Y J Wang
Journal:  PLoS One       Date:  2015-10-16       Impact factor: 3.240

7.  BCL3 exerts an oncogenic function by regulating STAT3 in human cervical cancer.

Authors:  Hu Zhao; Wuliang Wang; Qinghe Zhao; Guiming Hu; Kehong Deng; Yuling Liu
Journal:  Onco Targets Ther       Date:  2016-10-26       Impact factor: 4.147

8.  Non genomic loss of function of tumor suppressors in CML: BCR-ABL promotes IκBα mediated p53 nuclear exclusion.

Authors:  Sabrina Crivellaro; Cristina Panuzzo; Giovanna Carrà; Alessandro Volpengo; Francesca Crasto; Enrico Gottardi; Ubaldo Familiari; Mauro Papotti; Davide Torti; Rocco Piazza; Sara Redaelli; Riccardo Taulli; Angelo Guerrasio; Giuseppe Saglio; Alessandro Morotti
Journal:  Oncotarget       Date:  2015-09-22

Review 9.  Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias.

Authors:  Alessandro Morotti; Giovanna Carrà; Cristina Panuzzo; Sabrina Crivellaro; Riccardo Taulli; Angelo Guerrasio; Giuseppe Saglio
Journal:  Adv Hematol       Date:  2015-12-30

10.  Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects.

Authors:  Martin Culen; Marek Borsky; Veronika Nemethova; Filip Razga; Jiri Smejkal; Tomas Jurcek; Dana Dvorakova; Daniela Zackova; Barbora Weinbergerova; Lukas Semerad; Irina Sadovnik; Gregor Eisenwort; Harald Herrmann; Peter Valent; Jiri Mayer; Zdenek Racil
Journal:  Oncotarget       Date:  2016-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.